Slide 1: Exchange filing cover letter for Q1 FY25 results presentation
July 23, 2024 The National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (SYMBOL: THYROCARE) (SCRIP CODE 539871) Dear Sirs/Madam, Sub: Presentation- Unaudited financial results for
Slide 2: Thyrocare Earnings Presentation Q1 FY25
Thyrocare Earnings Presentation Q1 FY25
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable security laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied. Impor
Slide 4: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 02
Slide 5: Delivered 16% YoY revenue growth in Q1 FY25 while maintaining highest quality standards
Delivered 16% YoY revenue growth in Q1 FY25 while maintaining highest quality standards 30 Labs Acquisition of Polo (25 NABL Accredited) Labs Financial Parameters Operational Parameters Quality Parameters ► Consolidated Revenue for Active 8,100+ Samples 94% Q1 FY25 is Rs 157 Cr (16% (+7% YoY) Franch
Slide 6: 80% of our labs are now NABL accredited
80% of our labs are now NABL accredited 29 30* 28 25 17 7 Q1FY23 Q1FY24 Q1FY25 No of labs NABL labs NABL Labs (25) ► West : Navi Mumbai, Mumbai (Kurla), Pune, Raipur, Ahmedabad and Nagpur ► East : Kolkata, Bhubaneswar, Guwahati, Patna, Ranchi ► North : Bhopal, Jaipur, Delhi & covid lab, Gurgaon, Luc
Slide 7: New initiatives and expanding footprint
New initiatives and expanding footprint Acquisition of Polo Labs Private Limited Foray into Tanzania ► Thyrocare entered into a Business Transfer Agreement on 2nd July to acquire Polo Labs Private Limited. The transaction is expected to close by end of July 2024. ► Polo Labs is a pathology diagnosti
Slide 8: Strengthening our relationships with doctors and channel partners
Strengthening our relationships with doctors and channel partners Advisory Board Meeting with doctors Strengthening our Channel partners ► Hosted an Advisory Board Meeting in June 2024 with a ► Hosted channel partner meet to reward and strengthen our panel of esteemed doctors to gain insights on enh
Slide 9: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 07
Slide 10: Quarter health check - Financial Performance Q1 FY25
Quarter health check - Financial Performance Q1 FY25 YoY TTL Consolidated YoY Pathology Revenue +16% Revenue* +16% YoY Radiology YoY Normalized Revenue** +15% EBITDA +11% YoY Reported EBITDA +21% Normalized EBITDA% 29% * Pathology business excluding materials & others ** Radiology includes pulse hit
Slide 11: 16% YoY revenue growth in overall business; 11% YoY growth in Normalized EBITDA
16% YoY revenue growth in overall business ; 11% YoY growth in Normalized EBITDA Consolidated Revenue (Rs Cr) Normalized EBITDA (Rs Cr) +16% +11% 154.2 156.9 44.7 148.0 134.9 134.7 40.4 41.2 36.7 34.7 131.5 138.8 138.6 119.1 118.6 43.5 39.0 40.3 33.6 35.8 11.3 11.7 11.9 12.8 13.0 1.4 0.9 1.0 0.9 1.3
Slide 12: Franchise revenue grew by 11% YoY; Partnerships grew by 41% YoY
Franchise revenue grew by 11% YoY ; Partnerships (excluding API & B2G) grew by 41% YoY Pathology Revenue (Rs Cr) YoY% Pathology Workload (Lakhs) YoY% 86.6 88.5 +11% 43.6 +10% 83.5 42.2 79.7 39.7 40.1 76.0 36.6 46.8 41.5 +29% 36.6 35.2 32.0 15.7 15.8 +22% 26.6 14.4 13.3 23.2 26.1 +41% 12.9 18.9 22.6
Slide 13: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 11
Slide 14: Income statement - TTL Standalone: Jump in PAT by 46% YoY
Income statement - TTL Standalone : Jump in PAT by 46% YoY Quarter Growth % Pathology revenue grew by 16% YoY, INR crore Q1 FY25 Q4 FY24 Q1 FY24 Seq. YOY while the Franchise grew by 11%; Revenue from operations 143.6 141.2 123.6 2% 16% Partnerships (excluding API & B2G) Cost of materials consumed/so
Slide 15: Income statement - NHL Standalone
Income statement - NHL Standalone Quarter Growth % NHL Revenue grew 4% YoY on account INR crore Q1 FY25 Q4 FY24 Q1 FY24 Seq. YOY of increase in FDG sales. Revenue from operations 11.4 11.2 11.0 2% 4% Cost of materials consumed/sold (2.4) (2.5) (2.2) 3% 2% GM% decreased YoY on account of Gross margin
Slide 16: Income statement - TTL Consolidated: Jump in PAT by 35% YoY
Income statement - TTL Consolidated : Jump in PAT by 35% YoY Quarter Growth % Revenue from operations include INR crore Q1 FY25 Q4 FY24 Q1 FY24 Seq. YOY Pulse Hitech and Think Health. Revenue from operations 156.9 154.2 134.9 2% 16% Cost of materials consumed/sold (45.5) (46.6) (38.1) 4% 15% ESOPs p
Slide 17: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 15
Slide 18: Vision & Mission
Vision & Mission Global in our reach, excellence in our presence To ensure everyone has access to quality & affordable diagnostics 16
Slide 19: Our strategy remains to be a B2B service provider with an affordable value driven model
Our strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies Franchise Partnership + B2G ► Mom & Pop collection centres ► Online diagnostic aggregators ► Local labs ► Healthcare platforms 64% ► Nursing homes & hospitals ► Employee wellness platf
Slide 20: Going forward - Key pillars of growth
Going forward - Key pillars of growth Public & private International Franchise partnerships expansion ► Going deeper into India ► Focus on TB and Exploring to take our with focused test menu infectious disease along B2B model to emerging ► Strengthening our with large screening markets to deliver ex
Slide 21: Thank You
Q Thyrocare Tests you can trust For Any queries, please reach out to investor_relations@thyrocare.com Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to public